title: Perindopril improves six minute walking distance in older patients with left ventricular systolic dysfunction: a randomised double blind placebo controlled trial.
abstract: OBJECTIVE
  To evaluate the effects of the angiotensin converting enzyme inhibitor perindopril on six minute walking distance and quality of life in very old patients with left ventricular systolic dysfunction.
  
  
  METHODS
  Prospective, double blind placebo controlled trial.
  
  
  METHODS
  Medicine for the elderly day hospital.
  
  
  METHODS
  66 patients (average age 81) with left ventricular systolic dysfunction identified by echocardiography.
  
  
  METHODS
  10 weeks of treatment with titrated doses of perindopril or placebo.
  
  
  METHODS
  Six minute walking distance 10 weeks following treatment, quality of life measurements including the Minnesota living with heart failure questionnaire and the 36 item short form health survey.
  
  
  RESULTS
  In patients with left ventricular systolic dysfunction, six minute walking distance was significantly increased in the treatment group (37.1 m) compared with the placebo group (-0.3 m, p < 0.001). The medication was well tolerated and there were no significant adverse events.
  
  
  CONCLUSIONS
  Six minute walking distance is improved considerably by treatment with perindopril in older patients with heart failure caused by left ventricular systolic dysfunction.
authors.affiliation: Section of Ageing & Health, Department of Medicine, University of Dundee, Ninewells Hospital, Dundee, UK.
authors.forename: S D
authors.initials: SD
authors.lastname: Hutcheon
authors.forename: N D
authors.initials: ND
authors.lastname: Gillespie
authors.forename: I K
authors.initials: IK
authors.lastname: Crombie
authors.forename: A D
authors.initials: AD
authors.lastname: Struthers
authors.forename: M E T
authors.initials: ME
authors.lastname: McMurdo
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D020913:Perindopril / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D018487:Ventricular Dysfunction, Left / Q000188:drug therapy* / Q000503:physiopathology; D016138:Walking
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D020913:Perindopril